Only about 15% of the potential candidates for lung donation are considered suitable for transplantation. A new method for ex vivo lung perfusion (EVLP) has been developed and can be used for evaluation and reconditioning of "marginal" and unacceptable lungs. The ´purpose of this study is to analyse the executability and safety of ex vivo lung perfusion pulmonary ex vivo in marginal donors.
Donor Inclusion criteria: * Age \< 55 years-old; * Smoking history \< 20 pack-year; * Clear chest radiograph; * Absence of significant chest trauma; * Absence of purulent secretions and gastric contents at bronchoscopy; * PaO2 \< 300 mm Hg (FIO2 1.0, PEEP 5 cmH2O) Exclusion criteria: * Lungs presenting PO2 \< 400 mmHg after ex vivo lung perfusion
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Evaluation and reconditioning of lungs following lung transplantation
INCOR - Heart Institute
São Paulo, São Paulo, Brazil
30-days mortality
Time frame: 30 days after ex vivo lung transplantation
Respiratory complications (primary graft dysfunction, infection, rejection, bronchiolitis obliterates syndrome)
Time frame: 30 days after the ex vivo lung transplantation
12-months survival
Time frame: 12 months survival after ex vivo lung transplantation
Oxygenation index (PaO2/FiO2)on ICU arrival and 72 hours
Time frame: 72 hours after ex vivo lung transplantation
Mechanical ventilation time
Time frame: 30 days after ex vivo lung transplantation
Hospital and ICU time of stay
Time frame: 12 months after ex vivo lung transplantation
Non-respiratory complications (arrhythmia, renal failure, sepsis)
Time frame: 30 days after ex vivo lung transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.